pegylated liposomal doxorubicin / Generic mfg. - LARVOL DELTA

Retrospective analysis of R-CDOP efficacy and safety in frail patients with DLBCL compared to R-CHOP in fit patients (ASH 2025) - "Introduction: R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) remains a frontline treatment for DLBCL...Pegylated liposomal doxorubicin (PLD) compared with doxorubicin has demonstrated a more favorable hematologic toxicity profile in breast cancer treatment... Patients in the R-CDOP group demonstrated greater age, lower EF, and more aggressive disease subtype than those in the R-CHOP group. There was no evidence of increased hematopoietic or cardiac adverse events in the R-CDOP group compared to the R-CHOP group. DFS was comparable while the OS was lower in the R-CDOP group, suggesting death from non-relapse etiologies."

Retrospective data • B Cell Lymphoma • Breast Cancer • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Heart Failure • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Solid Tumor • Thrombocytopenia

Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study (ASH 2025) - P=N/A | "Pegylated liposomaldoxorubicin (PLD) offers a promising alternative to conventional doxorubicin, leveraging enhancedpermeability and retention effects for longer circulation and less cardiotoxicity...Thepatients received R-CDOP: Rituximab (375mg/m2, d0), PLD (30-35mg/ m2, d1), Cyclophosphamide(750mg/ m2, d1), Vindesine (3mg/ m2, d1) / Vincristine (1.4mg/m2, d1) and Prednisone (60mg/ m2, d1-5)every 21 days for 4 (Limited-stage lymphoma) or 6 (Advanced lymphoma) cycles with an additional 2cycles of Rituximab therapy... The preliminary results of the study demonstrated promising efficacy and a manageablesafety profile for the R-CDOP regimen in treatment-naïve NHL patients with high tumor burden,supporting further investigation."

Clinical • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Large B Cell Lymphoma • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • CD20

Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor. (PubMed, Front Oncol) - "Following early relapse to surgery, the patient sequentially failed treatment with pegylated liposomal doxorubicin (PLD), sorafenib, and a combination of doxorubicin and dacarbazine. Albeit rarely lethal in general, DT can exert life-threatening danger by local infiltration into vital tissue, such as blood vessels. The presented case highlights the novel γ-secretase inhibitor nirogacestat as a highly effective therapy preventing infiltration of the right carotid artery by a remarkably refractory DT."

Journal • Desmoid Tumors • Oncology • Sarcoma • Solid Tumor

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma (clinicaltrials.gov) - P3 | N=130 | Not yet recruiting | Sponsor: AIDS Malignancy Consortium | Trial completion date: Dec 2029 ➔ Nov 2027 | Trial primary completion date: Mar 2028 ➔ Dec 2026

Head-to-Head • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Sarcoma • Solid Tumor

Pegylated liposomal doxorubicin-based neoadjuvant immunochemotherapy for early-stage TNBC: A Taiwanese multicenter experience (ESMO Asia 2025) - "While this study predominantly used conventional anthracycline (doxorubicin or epirubicin), pegylated-liposomal doxorubicin (PLD) represents an alternative anthracycline formulation that may be used in pembrolizumab-based regimens. Whether PLD offers clinical benefit remains unclear, and real-world evidence is lacking to guide clinical practice. A total of 52 patients with stage I-III triple-negative breast cancer received neoadjuvant sequential taxane-platinum (4 cycles) followed by PLD-cyclophosphamide (4 cycles), with concurrent pembrolizumab (100mg or 200mg, Q3W), at five medical centers in Taiwan (2020-2024)... This retrospective study reveals the real-world evidence of sequential PLD with pembrolizumab therapy in early-stage TNBC patients. Notably, pCR and rCR rates in this multicenter cohort were lower than those reported in the KEYNOTE-522 trial, but trends favored the dose of 200 mg pembrolizumab (Q3W), suggesting a potential dose-response relationship. Ki-67..."

Clinical • Oncology • Triple Negative Breast Cancer

Balancing stability and activation: A pseudoparabolic activity spectrum guides fatty acid chain length optimization in prodrug-albumin nanoparticles. (PubMed, J Control Release) - "With 50.4× higher AUC and 77 % lower cardiac accumulation than DOX and enhanced early tumor targeting over Doxil®, palmitic acid (C16) was identified as the "sweet-spot" chain length for designing prodrug-HSA-based nanoparticles. These findings provide crucial rational design principles and a highly promising candidate strategy for developing promising albumin nanomedicines with the potential for enhanced efficacy and reduced toxicity."

Journal • Oncology • CTSB

Obesity Boosts the Tumor Delivery and Anticancer Effects of Liposomal Doxorubicin by an Apolipoprotein E-Mediated Mechanism. (PubMed, Mol Pharm) - "Herein, we demonstrate that pegylated liposomal doxorubicin (PLD) exhibits significantly enhanced antitumor and antimetastatic efficacy in obese breast tumor-bearing mice compared to normal controls...Conversely, supplementation with recombinant ApoE restores these effects in ApoE-deficient mice and potentiates PLD's antitumor efficacy. Collectively, our findings demonstrate obesity-induced ApoE as a pivotal regulator of the protein corona that actively enhances tumor-targeted delivery of PLD, which offers a rational strategy for engineering protein-corona-mediated tumor-targeted nanomedicines."

Journal • Breast Cancer • Genetic Disorders • Obesity • Oncology • Solid Tumor • APOE

Phase I pilot of pegylated liposomal doxorubicin, CD40 agonist antibody CDX-1140, and Flt3 ligand CDX-301 in advanced HER2-negative breast cancer (SABCS 2025) - P1 | "As of June 24th, 2025 this trial is in dose expansion and has enrolled 23 of 30 evaluable patients (NCT05029999). The trial is currently open at University of Texas Southwestern Simmons Comprehensive Cancer Center, University of Chicago, University of Texas San Antonio Health Science Center, Johns Hopkins, and University of North Carolina."

Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD40 • CD8 • HER-2

A Pilot, Single-Arm, Phase II Trial of Tamoxifen plus Pegylated Liposomal Doxorubicin in Patients with Metastatic Triple Negative Breast Cancer (SABCS 2025) - P2 | "Future studies will explore potential synergy between antibody-drug conjugates that induce DNA-damage e.g. Sacituzumab govitecan and Tam as well as adding immune checkpoint inhibition to Tam and Doxil to improve patient outcomes. Status: The study is currently open to enrollment. Clinical trial information: (NCT 06434064)"

Clinical • IO biomarker • Metastases • P2 data • Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • TP73

Targeting dendritic cells with CD40 agonist-based triplet immunotherapy induces IL12B-driven tumor control in triple-negative breast cancers (SABCS 2025) - "Once tumors reached ~50 mm³, mice received pegylated liposomal doxorubicin (Doxil, day 1), recombinant Flt3 ligand (Flt3L, days 1-5), and a CD40 agonist antibody (CD40a, days 11, 14, 17) or monotherapy or doublet combinations...This CD40 agonist-based triplet immunotherapy reprograms the tumor microenvironment through coordinated APC activation and IL-12-driven CD4+ and CD8+ T cell responses. cDC1s are essential mediators of therapeutic efficacy, while macrophages and B cells adopt inflammatory and activated states but are dispensable for treatment effect. Tregs constrain treatment potency and are a rational co-target to improve responses in breast cancer."

IO biomarker • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • B2M • BATF3 • CD20 • CD40 • CD8 • CD80 • CD86 • CSF1R • CXCL9 • CXCR3 • FLT3 • HAVCR2 • IL12A • IL12B • LAG3

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. (PubMed, J Clin Oncol) - P3 | "Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs."

Journal • P3 data • Oncology • Ovarian Cancer • Solid Tumor

The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors (ASH 2023) - "The dosage of the drugs used in the original regimen was reduced, leading to the adoption of the term "mini-TEDDi-R." Each 21-day cycle involved the following treatments: intravenous rituximab at a dose of 375 mg/m2/day on days 1-2, oral temozolomide at a dose of 150 mg/m2/day on days 2-5, intravenous infusion of 30 mg/m2/day etoposide on days 2-5, intravenous infusion of 25 mg/m2 of pegylated liposomal doxorubicin on day 2, intravenous infusion of dexamethasone at a dose of 10 mg/m2/BID on days 1-5, and oral zanubrutinib at a dose of 200mg/BID or oral orelabrutinib at a dose of 150mg/qd or oral ibrutinib at a dose of 560mg/qd from day 1 until neutrophil count <0.5*10^9/L or platelet count <30*10^9/L...Seven patients (29.2%) showed triple resistance to MTX, Ara-c, and BTK inhibitors... The mini-TEDDi-R regimen demonstrated a favorable remission rate in patients with DLBCL involving the CNS. The treatment was well-tolerated, and patients with tumors that..."

Clinical • B Cell Lymphoma • Bone Marrow Transplantation • CNS Disorders • CNS Lymphoma • CNS Tumor • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia • Transplantation

Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer. (PubMed, Curr Oncol) - "She received carboplatin/paclitaxel plus avelumab, followed by pegylated liposomal doxorubicin and weekly paclitaxel. This case illustrates that T-DXd can induce deep and durable remission in HER2-positive, dMMR metastatic serous endometrial cancer after multiple lines of therapy. It adds real-world evidence supporting further investigation of HER2-directed antibody-drug conjugates in gynaecologic malignancies, and underscores the need for confirmatory trials and refined biomarker-driven patient selection."

Journal • Cardiovascular • Cough • Endometrial Cancer • Gynecologic Cancers • Gynecology • Hematological Disorders • Interstitial Lung Disease • Neutropenia • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2 • MUC16

Tumor-Specific Delivery of Nanomedicines via a Nutrient Sensing-Driven Pathway Mediated by Niemann-Pick C1-Like 1. (PubMed, ACS Nano) - "After the underlying molecular mechanism was clarified, the CSD strategy was utilized to reconstruct the commercial anticancer Doxil nanoformulation and fabricate tumor-specific gene delivery nanovehicles. CSD-NPs exhibited enhanced antitumor activity at low doses with an inhibition rate of approximately 90% for both chemotherapy and gene therapy and substantially extended survival. In conclusion, the reported cholesterol surface-display strategy offers a promising platform for developing nanomedicines with advanced therapeutic functions."

Journal • Gene Therapies • Liver Cancer • Oncology • Solid Tumor

Long-acting lipid-based nanomedicines: rethinking from structure-based rational design to in vivo fate evaluation. (PubMed, J Control Release) - "For instance, polyethylene glycol (PEG)-modified liposomes show enhanced pharmacokinetic (PK) parameters such as half-life and area under the curve, yet their benefits, as observed with Doxil®, often fail to meaningfully surpass free doxorubicin...We critically assessed existing analytical methods and proposed strategies that integrate both temporal and spatial dimensions to better capture the dynamic fate of LaLBNs. By reframing LaLBNs as active biological entities rather than inanimate carriers, we advocate a paradigm shift from merely prolonging circulation to comprehensively orchestrating the entire delivery process, thereby narrowing the gap between nanocarrier design and therapeutic performance."

Journal • Preclinical • Review

Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin. (PubMed, Cost Eff Resour Alloc) - P3 | "This research will provide valuable insights into the cost-effectiveness of these treatments in managing KS. The results of this analysis will have important implications for healthcare providers and policymakers, offering guidance on the optimal treatment approach for HIV-infected individuals with KS."

Head-to-Head • HEOR • Journal • P3 data • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Sarcoma • Solid Tumor

TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16). (PubMed, Clin Pharmacokinet) - P1 | "Targeted liposomal doxorubicin demonstrated prolonged systemic circulation and low variability in liposomal drug release, likely due to its formulation characteristics. At 40 mg/m2 every 3 weeks, TLD-1 was well tolerated and showed modest preliminary antitumor activity in advanced breast cancer."

Journal • P1 data • PK/PD data • Platinum resistant • Breast Cancer • Dermatology • Hematological Disorders • Mucositis • Oncology • Ovarian Cancer • Solid Tumor • Stomatitis

MAINTENANCE PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS ACTIVE SURVEILLANCE FOR ADVANCED SOFT TISSUE SARCOMA PATIENTS WHO HAD CONTROLLED DISEASE AFTER STANDARD ANTHRACYCLINE-BASED TREATMENT (MELODY) (CTOS 2025) - "N/A"

Clinical • Metastases • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

INTEGRATING SARCULATOR AND PET RESPONSE TO GUIDE NEOADJUVANT TREATMENT DECISIONS IN HIGH-RISK SOFT TISSUE SARCOMA (CTOS 2025) - "The objective of this study was to determine how Positron Emission Tomography (PET) response to neoadjuvant chemotherapy outcomes compare to baseline risk estimates using SARCULATOR. Sixty-nine patients with high-grade STS received preoperative pegylated liposomal doxorubicin and ifosfamide. Metabolic response assessed by PET provides significantly stronger prognostic stratification than SARCULATOR alone. As predictive models evolve to incorporate dynamic, real-time data throughout the treatment course, PET response should be recognized as a critical factor. In this study, patients with a metabolic response had substantial improvements in long-term OS and PFS."

Clinical • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

CLINICOPATHOLOGICAL FEATURES AND OUTCOMES OF PATIENTS WITH KAPOSI SARCOMA: A SINGLE CENTER RETROSPECTIVE REAL WORLD ANALYSIS (CTOS 2025) - "Systemic treatment was administered to 45% of patients during their disease course, most commonly with pegylated liposomal doxorubicin(PLD, 78%), followed by paclitaxel(25%), and etoposide(25%). This real-world, single-center study highlights the clinical heterogeneity of KS and the diversity of treatment approaches. Chemotherapeutic agents demonstrated encouraging efficacy and manageable toxicity profiles, particularly PLD. However, the disease often remains a chronic, relapsing disease requiring diverse treatment approaches."

Real-world • Real-world evidence • Retrospective data • Kaposi Sarcoma • Oncology • Sarcoma • Solid Tumor

Clinical translation of nanomedicines for brain diseases: Current challenges and future directions. (PubMed, J Control Release) - "Since the approval of Doxorubicin Liposomal (Doxil®) by the U.S. Food and Drug Administration (FDA) in 1995, the field of nanomedicine has undergone substantial growth, transforming the landscape of drug delivery...The blood-brain barrier (BBB) hurdle and the intricate complexity of the central nervous system (CNS) significantly hinder the development of brain-targeted nanotherapeutics. In this review, we will summarize the current challenges encountered in developing nanomedicines for brain diseases and explore potential strategies to overcome these barriers, aiming to accelerate their translation into clinical practice."

Journal • Review • CNS Disorders

Short-chain dense brush PEGylation on rigid nanocarriers overcomes anti-PEG antibody recognition for immune-stealth drug delivery. (PubMed, Biomaterials) - "At equivalent PEG concentrations, ELISAs revealed near-background binding of anti-PEG IgG (6.3) and IgM (AGP3) to MSN-PEG500, in sharp contrast to the strong recognition of PEG2000-based Lipodox...Mechanistic studies implicated complement activation in PEG2000-associated immunotoxicity; C3 blockade with compstatin attenuated hypothermia (median ΔT reduced from ∼10 °C to ∼2 °C) in sensitized hosts. These findings indicate that nanoscale control of PEG conformation governs immune recognition and safety, offering a clinically tractable blueprint for engineering immune-evasive nanotherapeutics."

Journal • Immunology • Oncology

Role of Pegylated Liposomal Doxorubicin in Heavily Pretreated Relapsed Refractory Hodgkin Lymphoma Eligible for Autologous or Allogeneic Transplantation (ASH 2023) - "In the context of relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), various conventional single agents and salvage chemotherapy regimens have been explored, including bendamustine, brentuximab vedotin, nivolumab, and pembrolizumab. The findings from this retrospective analysis suggest that PLD monotherapy may be effective in treating a subset of patients with multi-relapsed or refractory cHL. PLD could be considered as a strategic and relatively low-toxicity bridging therapy option for patients undergoing transplantation."

Cardiovascular • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Thrombosis • Transplantation

Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer. (PubMed, Cancer Lett) - "Notably, co-administration with pegylated liposomal doxorubicin, a clinically approved chemotherapeutic agent, produced a synergistic effect, further enhancing tumor suppression. These findings support the potential of VS10, delivered via albumin-stabilized nanocrystals, as a promising second line therapy for OC."

Journal • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - P2/3 | N=260 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Trial completion • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor • BRAF